Search Results

You are looking at 1 - 10 of 21 items for :

  • NE Slovenia x
  • Haematology, Oncology x
Clear All
Open access

Irena Oblak, Primoz Petric, Franc Anderluh, Vaneja Velenik and Peter Fras

Radiat Oncol Biol Phys 2005; 63 : 1316-24. Cancer incidence in Slovenia 2003. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2006. Cancer incidence in Slovenia 2004. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2007. Cancer incidence in Slovenia 2005. Ljubljana: Institute of Oncology Ljubljana, Cancer Registry of Republic of Slovenia; 2008. Cancer incidence in Slovenia 2006. Ljubljana

Open access

Uros Smrdel, Marija Skoblar Vidmar and Ales Smrdel

Introduction Glioblastoma is the most common primary brain tumour. And while it accounts in Slovenia only for around 1.5 % of all tumours, it is also responsible for 2.5 % of cancer related deaths. The incidence of glioblastoma is slowly increasing, but marked increase of the incidence in the older population; especially in the over 70 year of age has been noted. 1 , 2 , 3 , 4 , 5 , 6 , 7 Unlikely many other tumours, the natural history of glioblastoma is also changing with the age of the patients. While prognosis in the patients under 50 is relatively

Open access

Erika Matos, Branko Zakotnik and Cvetka Grasic Kuhar

, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. [Abstract]. Breast Cancer Res Treat 2005; 94(Suppl 1): A-1. 11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84. 12. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer

Open access

Irena Oblak, Marija Skoblar Vidmar, Franc Anderluh, Vaneja Velenik, Ana Jeromen and Jasna But Hadzic

References 1. Cancer in Slovenia 2009. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2013. 2. Buyukasik O, Hasdemir AO, Gulnerman Y, Col C, Ikiz O. Second primary cancers in patients with gastric cancer. Radiol Oncol 2010; 44: 239-43. 3. Rajev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 2010; 11: 14-23. 4. Buergy D, Lohn F, Baack T, Siebenlist K, Haneder S, Michaely H, et al

Open access

Dominika Novak Mlakar, Tatjana Kofol Bric, Ana Lucija Škrjanec and Mateja Krajc

colorectal cancer screening.] [Slovenian] First Ljubljana Nacionalni inštitut za javno zdravje 2016 17 International Classification of Diseases for Oncology, 3rd Edition. Geneva, Switzerland: World Health Organization; 2000. International Classification of Diseases for Oncology 3rd Geneva, Switzerland World Health Organization 2000 18 Hakama M, Auvinen A, Day NE, Miller AB. Sensitivity in cancer screening. J Med Screen 2007; 14 : 174-7. 10.1258/096914107782912077 Hakama M Auvinen A Day NE Miller AB. Sensitivity in cancer screening J Med Screen 2007 14 174 7 10

Open access

Bojan Sedmak, Tina Eleršek, Olga Grach-Pogrebinsky, Shmuel Carmeli, Nataša Sever and Tamara Lah

Y, Vardi A, Sukenik A, Carmeli S, Börner T, et al. Towards clarification of the biological role of microcystins, a family of cyanobacterial toxins. Environm Microbiol 2007; 9: 965-70. Sedmak B, Kosi G. The role of microcystins in heavy cyanobacterial bloom formation. J Plankton Res 1998; 20: 691-708; 1998; 20: 1421. Sedmak B, Kosi G. Harmful cyanobacterial blooms in Slovenia - Bloom types and microcystin producers. Acta Biol Slovenica 2002; 45: 17-30. Grach-Pogrebinsky O, Sedmak B

Open access

Boris Jancar, Marjan Budihna, Brigita Drnovsek-Olup, Katrina Novak Andrejcic, Irena Brovet Zupancic and Dusica Pahor

than 8/million in Denmark and Norway. In Slovenia, the incidence of choroid melanoma between 1983-2009 was stable, at 7.8 cases/million for men and 7.4/million for women. 4 In the majority of patients, the biopsy of tumour is not indicated because the accuracy of clinical diagnosis is reaching 99%. 5 However, there is no agreement about the optimal therapy. 6 – 10 Until development of eye conserving therapies in 1960’s, for more than 100 years, enucleation was the only mode of treatment. The first among eye conserving approaches was the plaque brachytherapy 9

Open access

Irena Oblak, Franc Anderluh and Vaneja Velenik

, et al. Audit of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience. ANZ J Surg 2004; 74: 951-6. Park SH, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, et al. Postoperative chemotherapy for gastric cancer. Ann Oncol 2003; 14: 1373-7. Oblak I, Velenik V, Anderluh F, Strojan P. Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia. Eur J Surg Oncol 2007; 33: 982-7. Surenkok S

Open access

Matej Horvat, Uros Potocnik, Katja Repnik, Rajko Kavalar, Vesna Zadnik, Stojan Potrc and Borut Stabuc

Introduction Colorectal cancer (CRC) represents the third most common malignancy worldwide in men and second most common malignancy in women, accounting for approximately 10% of all tumour types worldwide and 8% of cancer related mortality. 1 In Slovenia according to Cancer registry of Slovenia yearly reports, CRC is the second most common cancer in men and women. The incidence was steadily increasing in the last decades. From 2001 to 2011 it has risen by 35%, from 1110 in 2001 to 1709 in 2010 when it reached its peak. The incidence is now declining with

Open access

Tanja Marinko, Jure Dolenc and Cvetka Bilban-Jakopin

after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36. 4. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneli V, et al. Trastuzumab containing regiments for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243. 5. Matos E. [Treatment of HER2 positive breast cancer patients]. [Slovenian]. Zdrav Vestn 2012; 81: 236-45. 6. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer Jr CE et al. Four-year follow-up of trastuzumab